BioStem Technologies, Inc. (BSEM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the S-1 for Q2 FY2026, filed Oct 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BSEM SEC filings page.
BioStem Technologies, Inc. (BSEM) reported $47.5M in revenue for fiscal year 2025, down 31.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of BioStem Technologies, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
BioStem Technologies, Inc. has an operating margin of -1.5%, meaning the company loses $1 on every $100 of revenue. This results in a profitability score of 66/100. This is down from 44.7% the prior year.
BioStem Technologies, Inc.'s revenue declined 31.8% year-over-year, from $69.7M to $47.5M. This contraction results in a growth score of 2/100.
BioStem Technologies, Inc. carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.12, BioStem Technologies, Inc. holds $4.12 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 88/100.
BioStem Technologies, Inc. converts 13.9% of revenue into free cash flow ($6.6M). This strong cash generation earns a score of 88/100.
BioStem Technologies, Inc. posts a -16.8% return on equity (ROE), meaning it loses $17 for every $100 of shareholders' equity. This results in a returns score of 76/100. This is down from 77.5% the prior year.
BioStem Technologies, Inc. scores 3.22, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($38.1M) relative to total liabilities ($10.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BioStem Technologies, Inc. passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
BioStem Technologies, Inc. reported a net loss of $6.6M while generating $9.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
BioStem Technologies, Inc. generated $7.9M in revenue in Q2 2026. This represents a decrease of 27.9% from the same quarter a year earlier.
BioStem Technologies, Inc.'s EBITDA was -$7.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4544.6% from the same quarter a year earlier.
BioStem Technologies, Inc. reported -$9.0M in net income in Q2 2026. This represents a decrease of 84631.8% from the same quarter a year earlier.
Cash & Balance Sheet
BioStem Technologies, Inc. held $7.0M in cash against $0 in long-term debt as of Q2 2026, with $21.2M of liabilities due within a year.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
BioStem Technologies, Inc.'s gross margin was 61.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 32.5 percentage points from the same quarter a year earlier.
BioStem Technologies, Inc.'s ROE was -32.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 32.5 percentage points from the same quarter a year earlier.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
BioStem Technologies, Inc. invested $734K in research and development in Q2 2026. This represents a decrease of 62.5% from the same quarter a year earlier.
Not reported for Q2 2026.
Not reported for Q2 2026.
BSEM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-1 | Q4'25S-1 | Q2'25S-1 | Q4'24S-1 |
|---|---|---|---|---|
| Revenue | $7.9M-27.9% | N/A | $11.0M | N/A |
| Cost of Revenue | $3.1M+346.4% | N/A | $685K | N/A |
| Gross Profit | $4.8M-52.9% | N/A | $10.3M | N/A |
| R&D Expenses | $734K-62.5% | N/A | $2.0M | N/A |
| SG&A Expenses | $6.5M-5.5% | N/A | $6.9M | N/A |
| Operating Income | -$8.4M-7550.1% | N/A | $113K | N/A |
| EBITDA | -$7.7M-4544.6% | N/A | $173K | N/A |
| Income Tax | $0-100.0% | N/A | $167K | N/A |
| Net Income | -$9.0M-84631.8% | N/A | $11K | N/A |
| EPS (Basic) | -$0.52 | N/A | $0.00 | N/A |
| EPS (Diluted) | -$0.52 | N/A | $0.00 | N/A |
| Diluted Shares (Avg) | 17M-26.0% | N/A | 23M | N/A |
Not reported in any period shown, so not listed: Interest Expense.
BSEM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-1 | Q4'25S-1 | Q2'25S-1 | Q4'24S-1 |
|---|---|---|---|---|
| Total Assets | $48.8M | $50.0M-14.2% | N/A | $58.3M |
| Current Assets | $20.8M | $44.4M-14.4% | N/A | $51.9M |
| Cash & Equivalents | $7.0M-77.4% | $29.5M+29.4% | $30.8M | $22.8M |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Inventory | $4.7M | $2.9M+57.7% | N/A | $1.8M |
| Accounts Receivable | $6.6M | $9.9M-57.3% | N/A | $23.1M |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Goodwill | $1.5M | $245K0.0% | N/A | $245K |
| Total Liabilities | $21.2M | $10.9M-40.5% | N/A | $18.3M |
| Current Liabilities | $21.2M | $10.8M-40.0% | N/A | $18.0M |
| Non-Current Liabilities | $1K | $105K-68.1% | N/A | $330K |
| Long-Term Debt | $0 | $0-100.0% | N/A | $150K |
| Total Equity | $27.6M-41.5% | $39.1M-2.2% | $47.2M | $40.0M |
| Retained Earnings | -$39.0M | -$21.2M-45.1% | N/A | -$14.6M |
BSEM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
BSEM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BioStem Technologies, Inc. BSEM | FY2025 | $47.5M | -$6.6M | -13.9% | $38.1M | 68/100 |
| SATELLOS BIOSCIENCE INC MSCLF | FY2025 | N/A | -$24.9M | N/A | $187.7M | — |
| NUO THERAPEUTICS INC NEW AURX | FY2025 | $3.3M | -$2.5M | -75.8% | $63.4M | — |
Where BioStem Technologies, Inc. Ranks
Frequently Asked Questions
What is BioStem Technologies, Inc.'s annual revenue?
BioStem Technologies, Inc. (BSEM) reported $47.5M in total revenue for fiscal year 2025. This represents a -31.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BioStem Technologies, Inc.'s revenue growing?
BioStem Technologies, Inc. (BSEM) revenue declined by 31.8% year-over-year, from $69.7M to $47.5M in fiscal year 2025.
Is BioStem Technologies, Inc. profitable?
No, BioStem Technologies, Inc. (BSEM) reported a net income of -$6.6M in fiscal year 2025, with a net profit margin of -13.9%.
What is BioStem Technologies, Inc.'s EBITDA?
BioStem Technologies, Inc. (BSEM) had EBITDA of -$470K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does BioStem Technologies, Inc. have?
As of fiscal year 2025, BioStem Technologies, Inc. (BSEM) had $29.5M in cash and equivalents against $0 in long-term debt.
What is BioStem Technologies, Inc.'s gross margin?
BioStem Technologies, Inc. (BSEM) had a gross margin of 93.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is BioStem Technologies, Inc.'s operating margin?
BioStem Technologies, Inc. (BSEM) had an operating margin of -1.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is BioStem Technologies, Inc.'s net profit margin?
BioStem Technologies, Inc. (BSEM) had a net profit margin of -13.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is BioStem Technologies, Inc.'s return on equity (ROE)?
BioStem Technologies, Inc. (BSEM) has a return on equity of -16.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BioStem Technologies, Inc.'s free cash flow?
BioStem Technologies, Inc. (BSEM) generated $6.6M in free cash flow during fiscal year 2025. This represents a -72.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioStem Technologies, Inc.'s operating cash flow?
BioStem Technologies, Inc. (BSEM) generated $9.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are BioStem Technologies, Inc.'s total assets?
BioStem Technologies, Inc. (BSEM) had $50.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are BioStem Technologies, Inc.'s capital expenditures?
BioStem Technologies, Inc. (BSEM) invested $3.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does BioStem Technologies, Inc. spend on research and development?
BioStem Technologies, Inc. (BSEM) invested $7.1M in research and development during fiscal year 2025.
What is BioStem Technologies, Inc.'s current ratio?
BioStem Technologies, Inc. (BSEM) had a current ratio of 4.12 as of fiscal year 2025, which is generally considered healthy.
What is BioStem Technologies, Inc.'s debt-to-equity ratio?
BioStem Technologies, Inc. (BSEM) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BioStem Technologies, Inc.'s return on assets (ROA)?
BioStem Technologies, Inc. (BSEM) had a return on assets of -13.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BioStem Technologies, Inc.'s P/E ratio?
BioStem Technologies, Inc. (BSEM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $38.1M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BioStem Technologies, Inc.'s price-to-sales ratio?
BioStem Technologies, Inc. (BSEM) trades at 0.8x sales, its market capitalization divided by revenue of $47.5M revenue, FY2025. The market capitalization is $38.1M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BioStem Technologies, Inc.'s Altman Z-Score?
BioStem Technologies, Inc. (BSEM) has an Altman Z-Score of 3.22, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is BioStem Technologies, Inc.'s Piotroski F-Score?
BioStem Technologies, Inc. (BSEM) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioStem Technologies, Inc.'s earnings high quality?
BioStem Technologies, Inc. (BSEM) reported a net loss of $6.6M while generating $9.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is BioStem Technologies, Inc.?
BioStem Technologies, Inc. (BSEM) scores 68 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.